J&J Dapoxetine Market Opportunity: Up To 60% Of Men Interested, PPD Says

Johnson & Johnson's Phase III premature ejaculation therapy dapoxetine will likely have a substantial market opportunity beyond the probable labeled indications for the drug, PPD CEO Fred Eshelman said during an investor conference Feb. 5